Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,501.65 0.00 0.00%
S&P 500 1,878.61 3.22 0.17%
NASDAQ 4,148.34 21.37 0.52%
Ticker Volume Price Price Delta
STOXX 50 3,189.81 13.84 0.44%
FTSE 100 6,703.00 28.26 0.42%
DAX 9,548.68 4.49 0.05%
Ticker Volume Price Price Delta
NIKKEI 14,404.99 -141.28 -0.97%
TOPIX 1,164.90 -8.91 -0.76%
HANG SENG 22,562.80 53.16 0.24%

Law Offices of Howard G. Smith Announces Class Action Lawsuit Against Dynavax Technologies Corporation



  Law Offices of Howard G. Smith Announces Class Action Lawsuit Against
  Dynavax Technologies Corporation

Business Wire

BENSALEM, Pa. -- June 22, 2013

Law Offices of Howard G. Smith announces that a class action lawsuit has been
filed in the United States District Court for the Northern District of
California on behalf of a class (the “Class”) comprising all purchasers of the
securities of Dynavax Technologies Corporation (“Dynavax” or the “Company”)
(NASDAQ:DVAX) between April 26, 2012 and June 10, 2013 (the “Class Period”).

Dynavax, a clinical-stage biopharmaceutical company, discovers and develops
novel products to prevent and treat infectious and inflammatory diseases. The
Complaint alleges that defendants issued materially false and misleading
statements throughout the Class Period regarding Dynavax’s biologic license
application for Heplisav, an investigational adult hepatitis B vaccine.

On June 10, 2013 Dynavax disclosed that in a meeting with the Food and Drug
Administration (“FDA”) over the Company’s license application for Heplisav,
the FDA expressed that it wanted additional safety data from more patients
before approving the drug. The FDA further expressed that analyzing Heplisav
for smaller groups of patients did not fully address its concerns and that it
would like to see additional safety trials. Moreover, as previously noted by
the FDA, there are also ongoing concerns regarding Dynavax’s manufacturing and
testing of Heplisav. On this news, shares of Dynavax declined $1.07 per share,
or 43.32%, to close on June 10, 2013, at $1.40 per share, on unusually heavy
volume.

No class has yet been certified in this action. Until a class is certified,
you are not represented by counsel unless you retain one. If you purchased
Dynavax stock during the Class Period, you have certain rights, and have until
August 19, 2013 to move for lead plaintiff status. To be a member of the class
you need not take any action at this time, and you may retain counsel of your
choice. If you wish to discuss this action or if you purchased Dynavax stock
prior to the Class Period and have any questions concerning this Notice or
your rights or interests with respect to these matters, please contact Howard
G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite
112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, Toll Free at
(888) 638-4847, or by email to howardsmith@howardsmithlaw.com, or visit our
website at http://www.howardsmithlaw.com.

Contact:

Law Offices of Howard G. Smith
Howard G. Smith, Esquire
(215) 638-4847
(888) 638-4847
howardsmith@howardsmithlaw.com
www.howardsmithlaw.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement